EGFR Inhibitor ABT-414

Known as: ABT-414 
An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, ABT-414 inhibits the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
01220162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR… (More)
Is this relevant?
2018
2018
BACKGROUND Epidermal growth factor receptor (EGFR) alterations are associated with multiple cancers. Current EGFR-directed… (More)
Is this relevant?
2017
2017
ABT-414 is an antibody-drug conjugate (ADC) being developed for the treatment of tumors harboring amplification of the epidermal… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2017
2017
Background We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly… (More)
Is this relevant?
2017
2017
Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2017
2017
Background The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety… (More)
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Targeting tumor-overexpressed EGFR with an antibody-drug conjugate (ADC) is an attractive therapeutic strategy; however, normal… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?